Comparison · NCT01222247-fbd1e599
Betamethasone vs Placebo: Neonatal Hyperbilirubinemia
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Betamethasone vs Placebo: Neonatal Hyperbilirubinemia. Trial comparisons, record NCT01222247-fbd1e599. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01222247-fbd1e599
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.117 | 0.101 | 0.135 | wilson | |
| Risk in group 2 | 0.1 | 0.0854 | 0.117 | wilson | |
| Risk difference, group 1 minus group 2 | 0.017 | -0.00596 | 0.04 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.17 | 0.947 | 1.45 | log | |
| Odds ratio, group 1 over group 2 | 1.19 | 0.94 | 1.51 | log | |
| Number needed to treat, for one more participant with the outcome on Betamethasone than on Placebo | 58.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Betamethasone | A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart | 167 | 1,427 | OG000 |
| Group 2 | Placebo | A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart~Placebo: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart. | 140 | 1,400 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Neonatal Hyperbilirubinemia
- Description
- Peak total bilirubin of at least 15 mg% or the use of phototherapy.
- Time frame
- Delivery
- Population
Source ClinicalTrials.gov
Trial
- Title
- Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
- NCT number
- NCT01222247
- Phases
- PHASE3
- Conditions
- Pregnancy, Respiratory Distress Syndrome, Pregnancy Outcomes, Preterm Birth
- Interventions
- Betamethasone, Placebo
- Lead sponsor
- The George Washington University Biostatistics Center
- Results first posted
- 2019-01-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01222247?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01222247-fbd1e599